Study on Lamivudine for Treating Relapsed or Resistant Solid Tumors

Inclusion Criteria

• Have a confirmed diagnosis of a solid tumor.
• The cancer must have worsened after previous treatment with PD-1 or PD-L1 antibodies.
• Have tried all standard treatments or decided not to pursue them.
• Have had no more than one additional treatment since the last PD-(L)1 therapy.
• Be willing to provide blood samples at specific times during the study.
• Be 18 years or older.
• Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Women of childbearing potential and men must agree to use effective contraception during the study and for three months after.
• Be able to understand and sign a consent form.
• Have adequate organ and bone marrow function.

Exclusion Criteria

• Have received chemotherapy within 14 days before starting the study.
• Have received radiotherapy within 7 days before starting the study, except for palliative care.
• Be taking other experimental drugs.
• Have uncontrolled illnesses, such as infections requiring antibiotics, heart failure, or unstable angina.
• Be pregnant or breastfeeding.
• Have an immune deficiency or be on immunosuppressive therapy within 7 days before the study.
• Have active autoimmune diseases requiring treatment in the past year.
• Have conditions or treatments that could interfere with the study results.
• Be HIV positive with a detectable viral load or not on stable treatment.
• Have active Hepatitis B or C.
• Have had a bone marrow or organ transplant.
• Have received a live vaccine within 30 days before the study.
• Have allergies to protein-based treatments.
• Have a history of severe immune-related side effects from previous treatments.
• Have lung diseases like interstitial lung disease or pneumonitis from previous cancer treatments.